HGEN - Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen ([[HGEN]] +4.7%) is trading higher after the company announced the publication of Phase 3 results of its lead asset lenzilumab in hospitalized COVID-19 patients.The Phase 3 data published online as a pre-print of medrxiv has yet to undergo the peer-review which typically precedes the publication on a medical journal.More than a fifth Humanigen shares are on loan.In November, the company first announced the top-line data from the trial which demonstrated 37% more recoveries in the lenzilumab arm compared to the current standard of care.In March, Humanigen said the experimental treatment raised the probability of survival by 54% without the need for invasive mechanical ventilation ("IMV") and the Phase 3 trial achieved the primary endpoint.

For further details see:

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy